Special Issue

Telemedicine across the Continuum of Cancer Care

Message from the Guest Editors

As you know, the use of video telemedicine visits (realtime videoconferencing between clinicians and patients) skyrocketed during the COVID-19 pandemic, including in oncology. While the details of telemedicine reimbursement by government pavers remains undetermined, it is difficult to imagine a world in which telemedicine is not an essential mode of healthcare delivery for years to come. For patients with cancer, telemedicine may be a particularly useful care-delivery modality, especially for those who suffer a significant burden in coming to clinic because of functional limitations, high symptom burden, financial strain, and/or distance from home to clinic. Telemedicine was rapidly implemented across the country during the pandemic, bypassing traditional steps historically taken to ensure a solid evidence base before launching a clinical delivery model. In this Issue, we aim to highlight manuscripts that will contribute to our understanding of how to provide the highest-quality, equitable clinical care by telemedicine in the future across the cancer care continuum, from cancer diagnosis to treatment, active surveillance, and palliative and hospice care.

Guest Editors

Dr. Brook Calton

Division of Palliative Care and Geriatrics, The Massachusetts General Hospital (MGH), Boston, MA 02115, USA

Dr. Vicki Jackson

Division of Palliative Care and Geriatrics, The Massachusetts General Hospital (MGH), Boston, MA 02115, USA

Deadline for manuscript submissions

closed (20 July 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/121001

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

